Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604653 · ClinicalTrials.gov registry record
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
A clinical trial of Colorectal Cancer and Ovarian Cancer, sponsored by Holy Name Medical Center.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT03604653 is a study of Colorectal Cancer and Ovarian Cancer that has completed, run by Holy Name Medical Center. The registered enrollment target is 10 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03604653, a study of Colorectal Cancer and Ovarian Cancer, has completed, sponsored by Holy Name Medical Center.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with primary peritoneal cancer or secondary peritoneal cancers from stomach, colorectal, appendiceal, and gynecological primary origin will be screened by pathology and staging to see if they are eligible to undergo cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). To be eligible for the study, patients must be over 18 years of age, have appropriate pathology and stage with disease confined to the peritoneal cavity, have a good performance status, have laboratory values that fall within safe ranges to undergo an operation and receive intraperitoneal chemotherapy. The chemotherapeutic agent and dose will be assigned based on pathological diagnosis in accordance with current standard of care. Surgery will be performed with the goal of removing all visible tumor that may require removal of adjacent organs. Once only microscopic disease is present, the chemotherapy will be delivered directly into the peritoneum via intraperitoneal hyperthermia and perfusion device. This will continue for 90 minutes. Patients will be followed for tumor response, survival, toxicity, complications, quality of life, and tumor markers. They will have regular follow up visits with the surgeon, undergo routine surveillance imagings, and receive follow up phone calls periodically.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Mitomycin c
- DEVICE HIPEC
- DRUG CDDP 50
- DRUG CDDP 75
Study Locations (1)
New Jersey
- Holy Name Medical Center - Teaneck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-05-15 |
| Est. Completion | 2021-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03604653
The ClinicalTrials.gov registry entry for NCT03604653 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Holy Name Medical Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT03604653 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03604653 about?
NCT03604653 is a clinical study titled "Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers". Patients with primary peritoneal cancer or secondary peritoneal cancers from stomach, colorectal, appendiceal, and gynecological primary origin will be screened by pathology and staging to see if they are eligible to undergo cytoreductive surgery combined with hyperthermic intraperitoneal chemothera...
What is the current status of trial NCT03604653?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2018-05-15. Estimated completion is 2021-05-01.
What conditions does trial NCT03604653 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Cervical Cancer, Fallopian Tube Cancer, Uterine Cancer.
What interventions are being tested in trial NCT03604653?
The interventions under investigation include: Doxorubicin (DRUG), Mitomycin c (DRUG), HIPEC (DEVICE), CDDP 50 (DRUG), CDDP 75 (DRUG).
Who is sponsoring clinical trial NCT03604653?
This trial is sponsored by Holy Name Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03604653 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.